Research Papers

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice

Publication: International Journal of Toxicity

Author(s): Jeffrey L Ambroso, John Dillberger, Rebecca Bruning-Barry, Tian Yang

7/2022

Tags: Pretomanid/PA-824

Male reproductive hormones in patients treated with pretomanid

Author(s): Boekelheide K, Olugbosi M, Nedelman J, Everitt D, Smith E, Betteridge M, Sun E, Spigelman M

6/2022

Tags: MDR-TB, Pretomanid/PA-824, XDR-TB

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys

Publication: Toxicology Reports

Author(s): Rebecca Bruning-Barry, Jeffrey L.Ambroso, John Dillberger, Tian J.Yang

4/2022

Tags: Pretomanid/PA-824

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

Publication: Antimicrobial Chemotherapy

Author(s): Anna Bateson, Julio Ortiz Canseco, Timothy D McHugh, Adam A Witney, Silke Feuerriegel, Matthias Merker, Thomas A Kohl, Christian Utpatel, Stefan Niemann, Sönke Andres, Katharina Kranzer, Florian P Maurer, et al.

3/2022

Tags: Drug-Sensitivity Testing, Pretomanid/PA-824

Pretomanid with Bedaquiline and Linezolid for Drug Resistant TB: A Comparison of Prospective Cohorts

Author(s): S. Oelofse, A. Esmail, A. H. Diacon F. Conradie, O. Olayanju, N. Ngubane, P. Howell, D. Everitt, A. M. Crook, C. M. Mendel, G. H. Wills, M. Olugbosi, A. del Parigi, E. Sun, A. Calatroni, M. Spigelman, K. Dheda

4/2021

Tags: Bedaquiline (TMC-207), Linezolid, MDR-TB, Pretomanid/PA-824

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

Publication: International Journal of Tuberculosis and Lung Disease

Author(s): C. D. Tweed, G. H. Wills, A. M. Crook

3/2021

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide, STAND/NC-006

The Clinical Dose of Pretomanid: An Exposure-Response Perspective

Author(s): Jerry R. Nedelman, David H. Salinger, Vishak Subramoney, Rob Woolson, Karen Wade, Mengchun Li, Daniel Everitt, Carl M. Mendel, Mel Spigelman

12/2020

Tags: BPaL, Clinical Development, Nix-TB, Pretomanid/PA-824

Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis

Author(s): Dalin Rifat , Si-Yang Li , Thomas Ioerger , Keshav Shah , Jean-Philippe Lanoix , Jin Lee , Ghader Bashiri , James Sacchettini , Eric Nuermberger

12/2020

Tags: M.tb. Biology, Pretomanid/PA-824

Phase 1 Study of the Effects of the Investigational Tuberculosis Treatment Pretomanid, Alone and in Combination with Moxifloxacin, on the QTc Interval in Healthy Volunteers

Author(s): Mengchun Li , George A Saviolakis , Wael El-Amin , Mamodikoe K Makhene , Blaire Osborn , Jerry Nedelman , Tian J Yang , Daniel Everitt

12/2020

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Publication: The New England Journal of Medicine

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., et al., for the Nix-TB Trial Team*

3/2020

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, Trial Design, XDR-TB

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Publication: The Lancet Respiratory Medicine

Author(s): Conor D Tweed, Rodney Dawson, Divan A Burger, Almari Conradie, Angela M Crook, Carl M Mendel, Francesca Conradie, Andreas H Diacon, Nyanda E Ntinginya, Daniel E Everitt, Frederick Haraka, Mengchun Li, Christo H van Niekerk, Alphonse Okwera

11/2019

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-005, PaMZ, Pretomanid/PA-824, Trial Design

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): David H. Salinger, Vishak Subramoney, Daniel Everitt, Jerry R. Nedelman

8/2019

Tags: BPaL, Pharmacokinetics, Pretomanid/PA-824

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Hanbin Li, David H. Salinger, Daniel Everitt, Mengchun Li, Angelo Del Parigi, Carl Mendel, Jerry R. Nedelman

7/2019

Tags: BPaL, Pharmacodynamics, Pretomanid/PA-824

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton, Mdluli, Fotouhi, Nuermberger EL

4/2019

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Antitubercular nitroimidazoles revisited: synthesis and activity of the authentic 3-nitro isomer of pretomanid

Publication: ACS Medicinal Chemistry Letters

Author(s): Andrew M. Thompson, Muriel Bonnet, Ho H. Lee, Scott G. Franzblau, Baojie Wan, George S. Wong, Christopher B. Cooper, William A. Denny

12/2017

Tags: Pretomanid/PA-824

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant...

Publication: Dawson R, Diacon AH, Everitt D, et. al. Efficiency and safety of.... Lancet. 2015 May 2;385(9979):1738-47. doi: 10.1016/S0140-6736(14)62002-X.

5/2015

Tags: Clinical Development, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-002, PaMZ, Pretomanid/PA-824, Pyrazinamide

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Publication: Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.

4/2015

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Development, Clinical Trial Results, Clofazamine, NC-003, Pretomanid/PA-824, Pyrazinamide, TB-HIV

Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis

Publication: Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):129

1/2015

Tags: Drug Discovery, Linezolid, Preclinical Data, Pretomanid/PA-824, Pyrazinamide, Sutezolid, TBA-354

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 withconcomitant lopinavir-ritonavir, efavirenz, or rifampin

Publication: Dooley KE, Luetkemeyer AF, Park JG, et. al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52.

9/2014

Tags: Clinical Development, Clinical Trial Results, Pharmacokinetics, Pretomanid/PA-824, TB-HIV

1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis

Publication: Chatterji M, Shandil R, Manjunatha MR, et. al. 1,4-azaindole, a potential drug candidate for treatment of tuberculosis.Antimicrob Agents Chemother. 2014 Sep;58(9):5325-31. doi: 10.1128/AAC.03233-14.

6/2014

Tags: Bedaquiline (TMC-207), Drug Discovery, MDR-TB, Pharmacokinetics, Preclinical Data, Pretomanid/PA-824